@article{0d1219abc6cb48cd8cf6e8727d58a0a1,
title = "Possible reduction of hepatoma formation by Smmu 7721 cells in SCID mice and metastasis formation by B16F10 melanoma cells in C57BL/6 mice by Agaricus blazei murill extract",
abstract = "Agaricus blazei Murill extract (ABM) has been reported to possess antitumor effects. In this study, the role of ABM in tumor growth and metastasis in vivo was evaluated in experimental Smmu 7721 hepatoma cells in severe combined immunodeficiency (SCID) mice and B16F10 melanoma cells lung metastasis in C57BL/6 mice. For the tumor growth model, the size of the liver tumor mass was about 10 mm to 20 mm in the control group. In comparison with the control group, the tumor mass seem to grow slowly with ABM treatment, especially at the high dose. For the tumor metastasis model, after a six-week treatment, the survival rates of B6 mice were 0%, 30%, 10% and 50% for control group, low, median and high concentration ABM treatment groups, respectively. The survival rate showed that pretreatment of C57BL/6 (B6) mice with ABM lengthened their lifespan after tumor cell inoculation, which supports the notion that ABM successfully reduced lung metastasis formation by B16F10 melanoma cells. The treatment effect was dependent on the concentration of ABM for tumor growth and metastasis in these models.",
keywords = "Agaricus blazei Murill, Antitumor effects, B16F10 melanoma cells, Smmu 7721 hepatoma cells",
author = "Wu, {Ming Fang} and Lu, {Hsu Feng} and Hsu, {Yu Ming} and Tang, {Ming Chu} and Chen, {Hsueh Chin} and Lee, {Ching Sung} and Yang, {Yi Yuan} and Yeh, {Ming Yang} and Chung, {Hsiung Kwang} and Huang, {Yi Ping} and Wu, {Chih Chung} and Chung, {Jing Gung}",
note = "Funding Information: From the Centre for Laboratory Medicine, Department of Clinical Chemistry, Tampere University Hospital, Tampere, Finland; Medical School, University of Tampere, Tampere, Finland; UKK Institute for Health Promotion Research, Tampere, Finland; and Wake Forest University School of Medicine, Winston-Salem, NC. Submitted November 7, 2000; accepted February 2, 2001. Supported by the grants from the Medical Research Fund of Tampere University Hospital, the Finnish Foundation for Cardiovascular Research, and the Finnish Ministry of Education. Address reprint requests to Riikka Malin, MSc, Tampere University Hospital, Laboratory of Atherosclerosis Genetics, FinnMedi 2, 3rd Floor, PO Box 2000, 33521 Tampere, Finland. Copyright {\textcopyright} 2001 by W.B. Saunders Company 0026-0495/01/5009-0011$35.00/0 doi:10.1053/meta.2001.25641",
year = "2011",
language = "English",
volume = "25",
pages = "399--404",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "3",
}